His-

Atty. Docket No: 07787.0042-00

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

e patent application of

ND, JAMES J. et al.

Serial No. 09/874,991

Filed: June 7, 2001

For: IMMUNOSTIMULATORY RNA/DNA HYBRID MOLECULES

## STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents Washington, D.C. 20231

BOX SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

- the submission, filed herewith in accordance with 37
   C.F.R. § 1.821(g), does not include new matter;
- 2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and
- 3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United

Serial No. 09/874,991

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

HARBOR CONSULTING

800-318-3021

Intellectual Property Services 1500A Lafayette Road Suite 262 Portsmouth, N.H.





## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of		)
James J. MOND et al.		) )
Serial No.: 09/874,991		) Group Art Unit: 1653
Filed: June 7, 2001		) ) Examiner: Unassigned
For:	IMMUNOSTIMULATORY RNA/DNA HYBRID MOLECULES	) ) )

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

## STATEMENT ACCOMPANYING SEQUENCE LISTING

Please associate the enclosed sequence listing with the above identified application. I hereby state that the content of the paper copy and the computer readable copy of the Sequence Listing submitted in accordance with 37 C.F.R. § 1.821(f) are the same. I hereby state that the paper copy and the computer readable form copy introduce no new matter and conform with standard Patent and Trademark Office requirements for the Sequence Listing in accordance with 37 C.F.R. §§ 1.821-1.825.

To the extent any extension of time under 37 C.F.R. § 1.136 is required to obtain entry of this response, such extension is hereby respectfully requested. If there are any fees due under 37 C.F.R. §§ 1.16 or 1.17 which are not enclosed herewith, including

FINNEGAN HENDERSON FARABOW GARRETT& DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com any fees required for an extension of time under 37 C.F.R. § 1.136, please charge such fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Bv:

Robert A. Pollock Reg. No. 43,008

Date: December 18, 2001

FINNEGAN HENDERSON FARABOW GARRETT& DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com